Skip to content

ALZAMEND NEURO, INC.: 10-Q filed 2022-12-12

What ALZAMEND NEURO, INC. reported in its quarterly report filed 2022-12-12 (fiscal Q2 2022): 25 published measures, 69 facts as tagged in accession 0001214659-22-014779.

This filing

Form
10-Q (quarterly report)
Filed
2022-12-12
Fiscal period
fiscal Q2 2022
Accession
0001214659-22-014779 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ALZAMEND NEURO, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2022-10-3110,424,876USD
At 2022-04-3014,516,443USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2022-10-311,637,453USD
At 2022-04-301,164,932USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2022-10-318,787,423USD
At 2022-07-3111,181,775USD
At 2022-04-3013,351,511USD
At 2021-10-3113,025,411USD
At 2021-07-3115,344,256USD
At 2021-04-302,012,945USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2022-10-319,182,812USD
At 2022-04-3014,063,811USD
At 2021-10-3113,572,692USD
At 2021-04-301,929,270USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2022-08-01 to 2022-10-31-3,109,991USD92
2022-05-01 to 2022-10-31-6,147,065USD184
2021-08-01 to 2021-10-31-3,599,929USD92
2021-05-01 to 2021-10-31-5,919,796USD184

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2022-05-01 to 2022-10-31-4,880,999USD184
2021-05-01 to 2021-10-31-3,268,834USD184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-05-01 to 2021-10-3114,912,256USD184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2022-10-31-35,341,560USD
At 2022-04-30-29,194,495USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2022-08-01 to 2022-10-3197,488,448shares92
2022-05-01 to 2022-10-3197,485,119shares184
2021-08-01 to 2021-10-3193,458,556shares92
2021-05-01 to 2021-10-3188,148,524shares184

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2022-08-01 to 2022-10-31-0.03USD/shares92
2022-05-01 to 2022-10-31-0.06USD/shares184
2021-08-01 to 2021-10-31-0.04USD/shares92
2021-05-01 to 2021-10-31-0.07USD/shares184

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2022-10-3190,489USD
At 2022-04-30102,909USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2022-05-01 to 2022-10-311,582,977USD184
2021-05-01 to 2021-10-312,020,006USD184

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2022-08-01 to 2022-10-31-3,106,403USD92
2022-05-01 to 2022-10-31-6,141,945USD184
2021-08-01 to 2021-10-31-3,583,934USD92
2021-05-01 to 2021-10-31-5,890,173USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2022-10-3110,334,387USD
At 2022-04-3014,413,534USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2022-08-01 to 2022-10-313,588USD92
2022-05-01 to 2022-10-315,120USD184
2021-08-01 to 2021-10-3115,995USD92
2021-05-01 to 2021-10-3129,623USD184

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2022-10-311,637,453USD
At 2022-04-301,164,932USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2022-10-31648,119USD
At 2022-04-301,162,850USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2022-08-01 to 2022-10-311,532,985USD92
2022-05-01 to 2022-10-312,908,940USD184
2021-08-01 to 2021-10-311,750,050USD92
2021-05-01 to 2021-10-312,666,458USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2022-10-3195,494,290shares
At 2022-04-3095,481,790shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2022-10-3159,002,729USD
At 2022-04-3057,419,753USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2022-10-31409,574USD
At 2022-04-30349,723USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2022-08-01 to 2022-10-311,573,418USD92
2022-05-01 to 2022-10-313,233,005USD184
2021-08-01 to 2021-10-311,833,884USD92
2021-05-01 to 2021-10-313,223,715USD184

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2022-05-01 to 2022-10-3112,420USD184

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2022-08-01 to 2022-10-31-3,588USD92
2022-05-01 to 2022-10-31-5,120USD184
2021-08-01 to 2021-10-31-15,995USD92
2021-05-01 to 2021-10-31-29,623USD184

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2021-05-01 to 2021-10-312,000,000USD184

Inspect the source

Entity
ALZAMEND NEURO, INC. / CIK 0001677077
Captured
2026-09-19T11:20:15.101Z
SEC response SHA-256
e091f00311cdd2d05377e177e0a2cf10b9fbab20ba26d0f97f3815f0b0cf6790

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001677077.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))